Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,242 across all filing types
Latest filing 2024-07-25 Declaration of Voting R…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed disclosure of voting results from the 39th Annual General Meeting (AGM) of Bliss GVS Pharma Limited held on July 25, 2024. It includes voting outcomes on multiple resolutions such as adoption of financial statements, dividend declaration, re-appointments of directors, and appointments of independent directors. The document references SEBI regulations and contains detailed vote counts and percentages for each resolution. There is no indication that this is the full annual report or financial statements, but rather the official results of shareholder votes at the AGM. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content confirm it is not a brief announcement or a report publication notice, but the actual voting results disclosure.
2024-07-25 English
Enclosed herewith the Disclsoure of Voting Results alongwith Scrutinizer Report for the 39th Annual General Meeting held on July 25, 2024.
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed disclosure of voting results from the 39th Annual General Meeting (AGM) of Bliss GVS Pharma Limited held on July 25, 2024. It includes voting outcomes on multiple resolutions such as adoption of financial statements, dividend declaration, re-appointments of directors, and appointments of independent directors. The document references SEBI regulations related to listing obligations and disclosure requirements, and contains detailed vote counts and percentages for each resolution. There is no indication that this is the full annual report or financial statements themselves, but rather the official announcement of the voting results and the scrutinizer's report. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)" filings, which are official results from shareholder votes at any general meeting. The document length and content confirm it is not a brief announcement or a certification, but a full disclosure of voting results. Therefore, the correct classification is DVA.
2024-07-25 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is a detailed disclosure addressed to stock exchanges about the proceedings of the 39th Annual General Meeting (AGM) held on July 25, 2024. It includes information about the meeting's conduct, attendees, agenda items, resolutions passed, and voting procedures. The text explicitly states it is the "Proceedings of 39th Annual General Meeting" and contains no financial statements or detailed financial data itself, but rather a narrative of the meeting events and resolutions. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. The document is over 11,000 characters, so it is not a brief announcement or a report publication notice. Therefore, the correct classification is AGM Information (AGM-R) with high confidence.
2024-07-25 English
Enclosed herewith proceedings of the 39th Annual General Meeting held on Thursday, July 25, 2024 at 11:00 a.m. through VC/OAVM.
AGM Information Classification · 100% confidence The document is a detailed disclosure addressed to stock exchanges about the proceedings of the 39th Annual General Meeting (AGM) held on July 25, 2024. It includes information about the meeting's conduct, attendance of directors and key management personnel, agenda items discussed, resolutions passed, and voting procedures. The document references the Annual Report and Auditors' Report but does not contain the full Annual Report or financial statements itself. It is a comprehensive summary of the AGM proceedings rather than the report or financial data. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. The document length (over 11,000 characters) and detailed content confirm it is not a brief announcement or a certification. Therefore, the correct classification is AGM Information (AGM-R).
2024-07-25 English
Financial Result Updates
Regulatory Filings
2024-07-24 English
Please find attached herewith the Outome of Board Meeting held on today i.e. July 24, 2024 for approval of Unaudited Standalone and Consolidated Financial Results of the Company for the ....
Regulatory Filings
2024-07-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.